ADPT

Adaptive Biotechnologies Corp

27.98

Nov 06 • 3:59 PM ET +1.15 (4.29%)

27.55

Aftermarket • 5:49 PM ET -0.43 (-1.55%)

Healthcare Diagnostics & Research USA Mid NASD

Nov 04, 10:58 PMAdaptive Biotechnologies posts first company-wide profit, beats Q3 EPS estimates and raises 2026 MRD revenue guidance to $276–$286M

Peers: NEO NTRA GH PSNL LH DGX VCYT TEM TXG CAI

| Held by: VTI IWM ARKG VB VXF IWO IBB FESM VBK VTWO

Scroll to Statements

Index	RUT
Market Cap	4.53B
Enterprise Value	4.65B
Income	-70.52M
Sales	298.01M
Book/sh	1.09
Cash/sh	1.85
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	624
IPO	Jun 27, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	15.20
P/B	25.65
P/C	15.15
P/FCF	-
EV/EBITDA	-
EV/Sales	15.59
Quick Ratio	3.87
Current Ratio	3.97
Debt/Eq	2.32
LT Debt/Eq	2.27
Option/Short	Yes / Yes

EPS (ttm)	-0.45
EPS next Y	-0.11
EPS next Q	-0.05
EPS this Y	-19.78%
EPS next Y	75.59%
EPS next 5Y	-
EPS past 3/5Y	34.64% 18.85%
Sales past 3/5Y	14.34% 23.00%
EPS Y/Y TTM	16.01%
Sales Y/Y TTM	17.91%
EPS Q/Q	-73.68%
Sales Q/Q	-10.72%
Earnings	Nov 04 AMC
EPS/Sales Surpr.	121.95% 17.23%

Insider Own	2.96%
Insider Trans	-35.68%
Inst Own	99.64%
Inst Trans	2.09%
ROA	-12.02%
ROE	-37.05%
ROIC	-12.24%
Gross Margin	71.62%
Oper. Margin	-15.58%
Profit Margin	-23.66%
SMA20	7.79%
SMA50	5.91%
SMA200	41.20%
Trades

Shs Outstand	161.57M
Shs Float	154.87M
Short Float	7.74%
Short Ratio	5.53
Short Interest	11.99M
52W High	30.74 -8.98%
52W Low	12.00 133.17%
Volatility	7.82% 6.17%
ATR (14)	1.65
RSI (14)	57.24
Beta	2.13
Rel Volume	1.54
Avg Volume	2.17M
Volume	3,333,597

Perf Week	5.03%
Perf Month	7.24%
Perf Quarter	9.94%
Perf Half Y	102.61%
Perf YTD	72.29%
Perf Year	79.82%
Perf 3Y	482.92%
Perf 5Y	-23.97%
Perf 10Y	-
Recom	1.00
Target Price	30.50
Prev Close	26.83
Price	27.98
Change %	4.29%

Consensus

Strong Buy

Avg. Price Target

$30.50

Implied Upside

+9.0%

Analysts12incl. previous ratings

Rating Distribution10 Buy · 1 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Dec 02, 2025	Resumed	MMorgan Stanley	Equal-Weight	$21	-24.9%
Sep 30, 2025	Initiated	GGuggenheim	Buy	$20	-28.5%
Jun 18, 2025	Initiated	CCraig Hallum	Buy	$15	-46.4%
Mar 21, 2025	Upgrade	GGoldman	Neutral → Buy	$9	-67.8%
Jul 05, 2023	Resumed	JJP Morgan	Overweight	$15	-46.4%
Jan 05, 2023	Initiated	BScotiabank	Sector Outperform	$15	-46.4%
Dec 21, 2022	Upgrade	PPiper Sandler	Neutral → Overweight	$7.50 → $14	-50.0%
Aug 25, 2022	Initiated	CCredit Suisse	Underperform	$8	-71.4%
Jun 03, 2022	Initiated	PPiper Sandler	Neutral	$7.50	-73.2%
Feb 16, 2022	Reiterated	JJP Morgan	Overweight	$75 → $50	+78.7%
Feb 16, 2022	Reiterated	GGoldman	Neutral	$54 → $21	-24.9%
Feb 16, 2022	Reiterated	BBTIG Research	Buy	$35 → $30	+7.2%
Feb 16, 2022	Reiterated	BBofA Securities	Buy	$40 → $32	+14.4%
Oct 15, 2021	Resumed	CCowen	Outperform
Mar 03, 2021	Downgrade	GGoldman	Buy → Neutral	$74 → $63	+125.2%
Oct 08, 2020	Resumed	BBTIG Research	Buy	$60	+114.4%
Sep 09, 2020	Initiated	MMorgan Stanley	Equal-Weight	$42	+50.1%
Jun 03, 2020	Initiated	GGoldman	Buy	$60	+114.4%
Jul 23, 2019	Initiated	BBTIG Research	Buy	$46	+64.4%
Jul 22, 2019	Initiated	WWilliam Blair	Outperform

Nov-04-26 06:57PM	Adaptive Biotechnologies Reaches Profitability Early As MRD Momentum Overshadows A Genentech-Distorted Revenue Decline (Earnings Whispers)
04:55PM	Adaptive Biotechnologies: Q3 Earnings Snapshot (Associated Press)
04:05PM	Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Oct-27-26 03:15PM	Adaptive Biotechnologies Must Show MRD Momentum Can Outrun Its Own Cautious Second-Half Guide (Earnings Whispers) +5.29%
Oct-14-26 04:05PM	Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire)
10:19AM	Loading…
Oct-09-26 10:19AM	Could You Have Seen The Run In Tempus AI Stock Coming? (Trefis)
Sep-25-26 08:03AM	Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure (GlobeNewswire)
Sep-17-26 08:00AM	Adaptive Biotechnologies Announces Update to NCCN Guidelines for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ (GlobeNewswire)
Sep-01-26 04:05PM	Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Aug-24-26 02:23PM	What Is Really Moving Tempus AI Stock Right Now? (Trefis)
Jul-30-26 01:03AM	Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ... (GuruFocus.com) +7.18%
Jul-29-26 04:41PM	Adaptive Biotechnologies: Q2 Earnings Snapshot (Associated Press)
04:05PM	Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-09-26 04:05PM	Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026 (GlobeNewswire) +8.13%
Jun-30-26 04:10PM	Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial (Exec Edge)
06:00AM	Loading…
Jun-17-26 06:00AM	Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering (GlobeNewswire)
Jun-15-26 04:10PM	Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses (GlobeNewswire)
04:05PM	Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering (GlobeNewswire)
May-29-26 07:30AM	At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ MRD Testing Across Hematology Clinical Practice and Research (GlobeNewswire)
May-21-26 04:17PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-05-26 05:01PM	Adaptive Biotechnologies: Q1 Earnings Snapshot (Associated Press)
04:05PM	Adaptive Biotechnologies Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-15-26 04:05PM	Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026 (GlobeNewswire)
Mar-02-26 08:10PM	Adaptive Biotechnologies CEO Flags MRD Momentum, Lifts 2025 Volume Outlook to 30%+ at TD Cowen Conf. (MarketBeat)
Feb-28-26 02:14AM	Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)? (Insider Monkey)
Feb-21-26 06:01AM	TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT) (Insider Monkey)
Feb-06-26 12:05AM	Adaptive Biotechnologies Corp (ADPT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-05-26 08:06PM	Adaptive Biotechnologies Q4 Earnings Call Highlights (MarketBeat)
07:30PM	Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:53PM	Loading…
04:53PM	Adaptive Biotechnologies: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Jan-27-26 04:05PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-22-26 04:05PM	Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 (GlobeNewswire) +8.48%
Jan-13-26 09:40AM	What's Going On With Adaptive Biotechnologies Shares Tuesday? (Benzinga)
Jan-12-26 09:06PM	Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026 (MarketBeat) +15.86%
07:30AM	Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results (GlobeNewswire)
Dec-30-25 04:05PM	Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 08:00AM	Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer (GlobeNewswire)
Dec-09-25 05:07PM	Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease (GlobeNewswire) +5.92%
Dec-08-25 02:16AM	Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake (Insider Monkey)
Dec-06-25 08:30AM	Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting (GlobeNewswire)
Nov-24-25 07:30AM	Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting (GlobeNewswire) +9.94%
Nov-22-25 10:10AM	Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why (Insider Monkey)
Nov-17-25 09:05AM	Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3 (Insider Monkey)
Nov-06-25 04:05PM	Adaptive Biotechnologies to Participate in Upcoming Investor Conferences (GlobeNewswire) -11.54%
07:05AM	Cathie Wood Loads Up Pinterest After Sell-Off -- Dumps Shopify, Roku, and Robinhood (GuruFocus.com)
12:03AM	Adaptive Biotechnologies Corp (ADPT) Q3 2025 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Nov-05-25 07:30PM	Adaptive Biotechnologies (ADPT) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
06:35PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:31PM	Adaptive Biotechnologies: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 07:45AM	Adaptive Biotechnologies Corp (ADPT) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-30-25 10:00AM	Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 10:00AM	Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-23-25 10:19AM	IQVIA Gears Up to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-17-25 12:10PM	Can This Red-Hot Biotech Stock Live Up to Wall Streets Expectations? (Barchart) -5.62%
Oct-15-25 04:05PM	Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire) +9.82%
Sep-26-25 10:32AM	LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy (Zacks)
09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
Sep-23-25 12:08PM	CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU (Zacks)
Sep-19-25 12:24PM	NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up (Zacks)
Sep-16-25 12:54PM	Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update (Zacks)
Sep-11-25 11:57AM	FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer (Zacks) +8.62%
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
09:40AM	Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks)
10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Sep-04-25 10:48AM	SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study (Zacks)
Sep-01-25 12:30PM	Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice (Zacks)
Aug-29-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-27-25 04:05PM	Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-25-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? (Zacks)
12:08AM	Adaptive Biotechnologies (ADPT) Poised for $33.7M Windfall on Genentech Deal Termination (Insider Monkey)
Aug-19-25 07:13AM	PTC drug for Friedrichs ataxia rejected; Lilly sells nearly $7B in bonds (BioPharma Dive)
Aug-13-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Aug-08-25 09:40AM	Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-06-25 07:01PM	Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday (Motley Fool) +5.79% +7.27%
03:30AM	Adaptive Biotechnologies Corp (ADPT) Q2 2025 Earnings Call Highlights: Strong MRD Growth and ... (GuruFocus.com)
Aug-05-25 07:30PM	Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings (Zacks)
06:00PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:57PM	Adaptive Biotechnologies: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:38AM	Adaptive Biotechnologies Corp (ADPT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.61%
Aug-01-25 08:10AM	Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-22-25 08:14AM	Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results (Insider Monkey)
Jul-15-25 04:05PM	Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 (GlobeNewswire)
Jul-04-25 09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
Jul-01-25 07:30AM	Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ MRD Testing into OncoEMR (GlobeNewswire)
Jun-26-25 09:49AM	Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains? (Zacks)
Jun-25-25 01:01PM	Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy (Insider Monkey) +12.49%
Jun-13-25 12:00PM	What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock (Zacks)
Jun-11-25 09:40AM	Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-03-25 04:05PM	Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors (Business Wire)
May-30-25 07:30AM	Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers (GlobeNewswire)
May-29-25 11:18AM	SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal (Zacks)
11:08AM	U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot (Zacks)
06:20AM	Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now? (Zacks)
May-28-25 04:05PM	Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RUBINSTEIN JULIE	President and COO	Oct 30 '26	Option Exercise	12.14	11,881	144,235	389,683	Nov 03 07:51 PM
RUBINSTEIN JULIE	President and COO	Nov 02 '26	Option Exercise	12.14	11,881	144,235	389,683	Nov 03 07:51 PM
RUBINSTEIN JULIE	President and COO	Nov 03 '26	Option Exercise	12.14	11,881	144,235	389,683	Nov 03 07:51 PM
RUBINSTEIN JULIE	President and COO	Oct 30 '26	Sale	26.73	11,881	317,596	377,802	Nov 03 07:51 PM
RUBINSTEIN JULIE	President and COO	Nov 03 '26	Sale	25.98	11,881	308,668	377,802	Nov 03 07:51 PM
RUBINSTEIN JULIE	President and COO	Nov 02 '26	Sale	25.47	11,881	302,627	377,802	Nov 03 07:51 PM
RUBINSTEIN JULIE	President and COO	Oct 27 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 29 07:52 PM
RUBINSTEIN JULIE	President and COO	Oct 28 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 29 07:52 PM
RUBINSTEIN JULIE	President and COO	Oct 29 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 29 07:52 PM
RUBINSTEIN JULIE	President and COO	Oct 28 '26	Sale	28.45	11,881	337,988	377,802	Oct 29 07:52 PM
RUBINSTEIN JULIE	President and COO	Oct 29 '26	Sale	28.27	11,881	335,876	377,802	Oct 29 07:52 PM
RUBINSTEIN JULIE	President and COO	Oct 27 '26	Sale	27.29	11,881	324,234	377,802	Oct 29 07:52 PM
RUBINSTEIN JULIE	President and COO	Oct 22 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 26 06:52 PM
RUBINSTEIN JULIE	President and COO	Oct 23 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 26 06:52 PM
RUBINSTEIN JULIE	President and COO	Oct 26 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 26 06:52 PM
RUBINSTEIN JULIE	President and COO	Oct 26 '26	Sale	26.04	11,881	309,409	377,802	Oct 26 06:52 PM
RUBINSTEIN JULIE	President and COO	Oct 23 '26	Sale	24.98	11,881	296,842	377,802	Oct 26 06:52 PM
RUBINSTEIN JULIE	President and COO	Oct 22 '26	Sale	24.51	11,881	291,206	377,802	Oct 26 06:52 PM
RUBINSTEIN JULIE	President and COO	Oct 19 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 21 06:36 PM
RUBINSTEIN JULIE	President and COO	Oct 20 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 21 06:36 PM
RUBINSTEIN JULIE	President and COO	Oct 21 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 21 06:36 PM
RUBINSTEIN JULIE	President and COO	Oct 21 '26	Sale	25.41	11,881	301,877	377,802	Oct 21 06:36 PM
RUBINSTEIN JULIE	President and COO	Oct 20 '26	Sale	24.53	11,881	291,473	377,802	Oct 21 06:36 PM
RUBINSTEIN JULIE	President and COO	Oct 19 '26	Sale	24.05	11,881	285,738	377,802	Oct 21 06:36 PM
RUBINSTEIN JULIE	President and COO	Oct 14 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 16 07:21 PM
RUBINSTEIN JULIE	President and COO	Oct 15 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 16 07:21 PM
RUBINSTEIN JULIE	President and COO	Oct 16 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 16 07:21 PM
RUBINSTEIN JULIE	President and COO	Oct 14 '26	Sale	25.68	11,881	305,072	377,802	Oct 16 07:21 PM
RUBINSTEIN JULIE	President and COO	Oct 15 '26	Sale	25.61	11,881	304,272	377,802	Oct 16 07:21 PM
RUBINSTEIN JULIE	President and COO	Oct 16 '26	Sale	24.24	11,881	288,011	377,802	Oct 16 07:21 PM
RUBINSTEIN JULIE	President and COO	Oct 09 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 13 07:05 PM
RUBINSTEIN JULIE	President and COO	Oct 12 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 13 07:05 PM
RUBINSTEIN JULIE	President and COO	Oct 13 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 13 07:05 PM
RUBINSTEIN JULIE	President and COO	Oct 09 '26	Sale	26.41	11,881	313,777	377,802	Oct 13 07:05 PM
RUBINSTEIN JULIE	President and COO	Oct 12 '26	Sale	25.51	11,881	303,127	377,802	Oct 13 07:05 PM
RUBINSTEIN JULIE	President and COO	Oct 13 '26	Sale	25.50	11,881	302,966	377,802	Oct 13 07:05 PM
RUBINSTEIN JULIE	President and COO	Oct 06 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 08 06:54 PM
RUBINSTEIN JULIE	President and COO	Oct 07 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 08 06:54 PM
RUBINSTEIN JULIE	President and COO	Oct 08 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 08 06:54 PM
RUBINSTEIN JULIE	President and COO	Oct 06 '26	Sale	27.75	11,881	329,698	377,802	Oct 08 06:54 PM
RUBINSTEIN JULIE	President and COO	Oct 07 '26	Sale	26.40	11,881	313,658	377,802	Oct 08 06:54 PM
RUBINSTEIN JULIE	President and COO	Oct 08 '26	Sale	25.66	11,881	304,866	377,802	Oct 08 06:54 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Oct 06 '26	Sale	30.00	6,444	193,320	389,350	Oct 08 06:52 PM
SUSAN BOBULSKY	Officer	Oct 06 '26	Proposed Sale	29.84	6,444	192,289		Oct 06 04:22 PM
RUBINSTEIN JULIE	President and COO	Oct 01 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 05 08:15 PM
RUBINSTEIN JULIE	President and COO	Oct 02 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 05 08:15 PM
RUBINSTEIN JULIE	President and COO	Oct 05 '26	Option Exercise	12.14	11,881	144,235	389,683	Oct 05 08:15 PM
RUBINSTEIN JULIE	President and COO	Oct 05 '26	Sale	29.19	11,881	346,815	377,802	Oct 05 08:15 PM
RUBINSTEIN JULIE	President and COO	Oct 02 '26	Sale	28.13	11,881	334,213	377,802	Oct 05 08:15 PM
RUBINSTEIN JULIE	President and COO	Oct 01 '26	Sale	28.05	11,881	333,301	377,802	Oct 05 08:15 PM
LO FRANCIS	Chief People Officer	Oct 01 '26	Option Exercise	6.78	26,792	181,557	247,659	Oct 05 08:12 PM
LO FRANCIS	Chief People Officer	Oct 01 '26	Sale	28.28	26,792	757,697	220,867	Oct 05 08:12 PM
JULIE RUBINSTEIN	Officer	Oct 01 '26	Proposed Sale	28.90	379,777	10,975,555		Oct 01 04:32 PM
LO FRANCIS	Chief People Officer	Sep 16 '26	Option Exercise	9.57	105,560	1,010,581	336,273	Sep 18 08:17 PM
LO FRANCIS	Chief People Officer	Sep 16 '26	Sale	28.06	115,406	3,238,004	220,867	Sep 18 08:17 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Sep 15 '26	Sale	27.00	1,195	32,265	395,794	Sep 17 06:50 PM
FRANCIS LO	Officer	Sep 16 '26	Proposed Sale	26.68	142,198	3,793,843		Sep 16 04:40 PM
SUSAN BOBULSKY	Officer	Sep 15 '26	Proposed Sale	24.78	1,195	29,612		Sep 15 04:35 PM
OWEN KATEY EINTERZ	Director	Aug 26 '26	Sale	26.00	9,615	249,990	78,639	Aug 28 05:50 PM
KATHERINE E OWEN	Director	Aug 26 '26	Proposed Sale	26.00	9,615	249,990		Aug 26 04:13 PM
Harlan Robins	Former Officer	Aug 20 '26	Proposed Sale	25.44	402,160	10,230,950		Aug 20 06:07 PM
HERSHBERG ROBERT	Director	Aug 18 '26	Option Exercise	6.32	15,000	94,800	77,347	Aug 20 05:55 PM
HERSHBERG ROBERT	Director	Aug 18 '26	Sale	24.40	30,664	748,208	46,683	Aug 20 05:55 PM
ROBINS CHAD M	CEO and Chairman	Aug 17 '26	Option Exercise	6.55	321,324	2,104,672	2,501,842	Aug 19 08:15 PM
ROBINS CHAD M	CEO and Chairman	Aug 18 '26	Option Exercise	6.55	278,676	1,825,328	2,459,194	Aug 19 08:15 PM
ROBINS CHAD M	CEO and Chairman	Aug 17 '26	Sale	25.08	321,324	8,060,043	2,180,518	Aug 19 08:15 PM
ROBINS CHAD M	CEO and Chairman	Aug 18 '26	Sale	24.48	278,676	6,822,123	2,180,518	Aug 19 08:15 PM
NEUPERT PETER M	Director	Aug 17 '26	Option Exercise	6.32	15,000	94,800	255,315	Aug 19 08:07 PM
NEUPERT PETER M	Director	Aug 17 '26	Sale	25.15	124,690	3,135,850	130,625	Aug 19 08:07 PM
Harlan Robins	Former Officer	Aug 19 '26	Proposed Sale	25.49	215,632	5,496,460		Aug 19 06:28 PM
ROBERT M HERSHBERG	Director	Aug 18 '26	Proposed Sale	24.40	30,664	748,303		Aug 18 06:17 PM
Chad Robins	Officer	Aug 18 '26	Proposed Sale	24.56	278,676	6,844,283		Aug 18 05:45 PM
Harlan Robins	Former Officer	Aug 18 '26	Proposed Sale	24.56	261,044	6,411,241		Aug 18 05:45 PM
Harlan Robins	Former Officer	Aug 17 '26	Proposed Sale	24.77	300,992	7,455,572		Aug 17 05:20 PM
Chad Robins	Officer	Aug 17 '26	Proposed Sale	24.77	321,324	7,959,195		Aug 17 05:20 PM
PETER NEUPERT	Director	Aug 17 '26	Proposed Sale	25.15	124,690	3,136,046		Aug 17 04:49 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Aug 10 '26	Sale	25.00	3,000	75,000	396,989	Aug 12 07:33 PM
SUSAN BOBULSKY	Officer	Aug 10 '26	Proposed Sale	24.93	3,000	74,790		Aug 10 04:37 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Jul 30 '26	Sale	24.00	1,299	31,176	399,989	Aug 03 06:26 PM
SUSAN BOBULSKY	Officer	Jul 30 '26	Proposed Sale	22.56	1,299	29,305		Jul 30 04:38 PM
ROBINS HARLAN S	Chief Scientific Officer	Jul 21 '26	Option Exercise	6.55	284,800	1,865,440	1,304,458	Jul 23 07:34 PM
ROBINS HARLAN S	Chief Scientific Officer	Jul 21 '26	Sale	21.89	492,400	10,780,409	812,058	Jul 23 07:34 PM
Harlan Robins	Officer	Jul 21 '26	Proposed Sale	22.58	492,400	11,118,392		Jul 21 05:20 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Jul 16 '26	Sale	23.00	5,000	115,000	401,288	Jul 20 07:19 PM
LO FRANCIS	Chief People Officer	Jul 15 '26	Option Exercise	8.91	105,762	942,691	336,475	Jul 17 07:23 PM
LO FRANCIS	Chief People Officer	Jul 15 '26	Sale	22.59	105,762	2,389,164	230,713	Jul 17 07:23 PM
SUSAN BOBULSKY	Officer	Jul 16 '26	Proposed Sale	22.90	5,000	114,500		Jul 16 04:34 PM
ROBINS HARLAN S	Chief Scientific Officer	Jul 02 '26	Sale	22.01	386,240	8,501,149	1,019,658	Jul 07 06:52 PM
LO FRANCIS	Chief People Officer	Jul 02 '26	Option Exercise	9.46	37,863	358,356	275,551	Jul 06 07:19 PM
LO FRANCIS	Chief People Officer	Jul 01 '26	Option Exercise	8.04	37,758	303,530	288,692	Jul 06 07:19 PM
LO FRANCIS	Chief People Officer	Jul 01 '26	Sale	22.45	51,004	1,144,792	237,688	Jul 06 07:19 PM
LO FRANCIS	Chief People Officer	Jul 02 '26	Sale	22.59	44,838	1,012,890	230,713	Jul 06 07:19 PM
BOBULSKY SUSAN	Chief Commercial Officer, MRD	Jul 01 '26	Sale	22.00	487	10,714	406,288	Jul 06 07:15 PM
Harlan Robins	Officer	Jul 02 '26	Proposed Sale	21.19	386,240	8,184,426		Jul 02 05:43 PM
FRANCIS LO	Officer	Jul 01 '26	Proposed Sale	21.45	199,260	4,274,127		Jul 01 04:35 PM
SUSAN BOBULSKY	Officer	Jul 01 '26	Proposed Sale	21.45	487	10,446		Jul 01 04:16 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Jun 29 '26	Option Exercise	7.28	103,295	751,602	376,046	Jun 30 07:25 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Jun 26 '26	Option Exercise	12.14	11,034	133,953	283,785	Jun 30 07:25 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Jun 29 '26	Sale	21.14	154,768	3,271,796	221,278	Jun 30 07:25 PM
BENZENO SHARON	Chief Commercial Ofc Imm Med	Jun 26 '26	Sale	21.00	11,034	231,714	272,751	Jun 30 07:25 PM

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Co-FounderMr. Chad M. Robins M.B.A.

President & COOMs. Julie Rubinstein

VPMr. Kyle Piskel

Chief Commercial Officer of MRDMs. Susan Bobulsky

FounderMr. Christopher Carlson Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADPT

Adaptive Biotechnologies Corp

Upgrade your Finviz experience